GSK and partner Alector said Tuesday their experimental drug for a rare form of dementia failed to meet its main goal in a late-stage trial.
The drug, latozinemab, was being evaluated in patients with frontotemporal dementia caused by a specific genetic mutation.
According to the companies, the treatment did not show a benefit in slowing the clinical progression of the disease.
While the drug did achieve a goal related to a biomarker by increasing levels of a protein called progranulin, this did not translate into a clinical benefit for patients.
GSK said preliminary safety data have not highlighted any major concerns.
As a result of the findings, the companies will discontinue further studies of the drug.
GSK and Alector entered into a collaboration to develop and commercialize the treatment in July 2021.
More from this issuer
Related coverage
GSK raised its full-year 2025 forecast on Wednesday, citing strong sales of its specialty medicines and vaccines and recent drug approvals, including for its cancer treatment Blenrep.
GSK said Thursday its cancer drug Blenrep won U.S. approval to treat adults with multiple myeloma that has returned or stopped responding to treatment, overcoming an earlier negative recommendation from a regulatory advisory panel.
GSK announced positive late-stage trial results for a new, low-carbon version of its widely used Ventolin asthma inhaler.
GSK and Spero Therapeutics on Tuesday announced positive late-stage trial results for their investigational oral antibiotic, tebipenem HBr, for treating complicated urinary tract infections (cUTIs).